Mrs. Helen Claire Russell- Tari, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 42084 State Highway 28, Margaretville, NY 12455 Phone: 845-586-2631 Fax: 845-586-1321 |
Leanne Legg, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 42084 Route 28, Box 200, Margaretville, NY 12455 Phone: 607-334-5010 Fax: 607-336-7326 |
News Archive
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
A worldwide consensus co-authored by more than 40 scientists sets out ways to address research bottlenecks as the international community strives to diagnose most rare genetic diseases by 2020.
The Associated Press/New York Times: Indiana has joined the lawsuit brought by 13 states challenging the constitutionality of a mandate on Americans to carry health insurance in the new health reform law. "State Attorney General Greg Zoeller said Monday that Indiana would be added to an amended version of the lawsuit against the law that is expected to be filed soon" (3/29).
Microplastics contaminate the world's surface waters, yet scientists have only just begun to explore their presence in groundwater systems.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
› Verified 5 days ago